Evidence map›Paper›PMID 37474509›Full record

ArticleNature communications2023

Identification of transcriptional programs using dense vector representations defined by mutual information with GeneVector.

Nicholas Ceglia, Zachary Sethna, Samuel S Freeman, Florian Uhlitz, Viktoria Bojilova, Nicole Rusk, Bharat Burman, Andrew Chow, Sohrab Salehi, Farhia Kabeer and 4 more

Abstract read
In one paragraph

Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Nicholas CegliaComputational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. ceglian@mskcc.org.
Zachary Sethna *Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Samuel S Freeman *Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Florian UhlitzComputational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Viktoria BojilovaComputational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Nicole RuskComputational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-2663-6288
Bharat BurmanDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Andrew ChowDepartment of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-1151-2450
Sohrab SalehiComputational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Farhia KabeerDepartment of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.
Samuel AparicioDepartment of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.
Benjamin D GreenbaumComputational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-6153-8793
Sohrab P ShahComputational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-6402-523X
Andrew McPhersonComputational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Center for Integrated Cellular Analysis - Valeria A. Sanchez EstradaRM1HG011014 · NHGRI · NEW YORK GENOME CENTER · PI LANDAU, DAN, SATIJA, RAHUL · 2020 to 2025
$22.1M
Targeting Polθ to Overcome PARP Inhibitor Resistance in Homologous Recombination Deficient Breast CancerP50CA247749 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Simon N. Powell · 2020 to 2026
$16.3M
Total Neoadjuvant Therapy (TNT) for Borderline Resectable and Locally Advanced Pancreatic AdenocarcinomaP50CA257881 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Christine A Iacobuzio-Donahue, Eileen Mary O'Reilly · 2022 to 2026
$14.3M
Understanding the Relationship of Repeat Expression and MetastasisR01CA240924 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI GREENBAUM, BENJAMIN, TING, DAVID TSAI · 2019 to 2023
$3.3M
A Statistical Physics Framework for Understanding the Role of Repeat RNA in Tumor ImmunityU01CA228963 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI GREENBAUM, BENJAMIN, TING, DAVID TSAI · 2020 to 2024
$3.2M
Group 2 Innate Lymphoid Cell Regulation of Pancreatic Cancer ImmunityR01CA262516 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI BALACHANDRAN, VINOD P, MERGHOUB, TAHA · 2022 to 2025
$2.8M
POTENTIATION OF ANTI-TUMOR IMMUNITY BY ONCOLYTIC VIRUS IN SITU VACCINATIONR01CA269382 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Dmitriy Zamarin · 2023 to 2026
$2.5M
The MSK Genomic Data Analysis Center for Tumor EvolutionU24CA264028 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SCHULTZ, NIKOLAUS, SHAH, SOHRAB P · 2021 to 2025
$2.1M
Cancer Research UK GC-243330NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA247749NCI NIH HHS P50 CA257881NCI NIH HHS R01 CA240924NCI NIH HHS R01 CA262516NCI NIH HHS R01 CA269382NCI NIH HHS U01 CA228963NCI NIH HHS U24 CA264028NHGRI NIH HHS RM1 HG011014
6 · The paper itself

Abstract

Deciphering individual cell phenotypes from cell-specific transcriptional processes requires high dimensional single cell RNA sequencing. However, current dimensionality reduction methods aggregate sparse gene information across cells, without directly measuring the relationships that exist between genes. By performing dimensionality reduction with respect to gene co-expression, low-dimensional features can model these gene-specific relationships and leverage shared signal to overcome sparsity. We describe GeneVector, a scalable framework for dimensionality reduction implemented as a vector space model using mutual information between gene expression. Unlike other methods, including principal component analysis and variational autoencoders, GeneVector uses latent space arithmetic in a lower dimensional gene embedding to identify transcriptional programs and classify cell types. In this work, we show in four single cell RNA-seq datasets that GeneVector was able to capture phenotype-specific pathways, perform batch effect correction, interactively annotate cell types, and identify pathway variation with treatment over time.

Indexed as

Gene Expression ProfilingSingle-Cell AnalysisCluster AnalysisExome SequencingPrincipal Component AnalysisSequence Analysis, RNA

Identifiers

PMID37474509
PMCPMC10359421

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.